Mark A. Wainberg, PhD
Director
McGill University AIDS Centre
Montreal, Quebec

Research Topics

• HIV drug resistance and pathogenesis
  
  
  

Lecture and Writing Topics

• New insights into HIV replication
• New antiretroviral drugs and targets
• HIV drug resistance
• Primary HIV infection and viral fitness
  
  
  

Current Professional Summary

Dr Wainberg is the Director of the McGill University AIDS Centre and a Professor of Medicine and Microbiology at McGill University in Montreal, Canada. He is a member of several World Health Organization committees on the topics of HIV drug resistance and treatment access for HIV-infected persons in developing countries. He was President of the Internatinal AIDS Society from 1998 to 2000. He is Co-chair of the 16th International Conference on AIDS, to take place in Toronto in August 2006.


Committees and Organizations

• President, International AIDS Society, 1998-2000
• President, Canadian Association for HIV Research, 1995-1997
• Member, World Health Organization committee on HIV drug resistance
• Chair, Scientific Review Committee, Ontario HIV Treatment Network
• Chair, Scientific Committee, French National AIDS Agency (ANRS)
  
  
  

Honors and Awards

• Officer of the Order of Canada, 2001
• Fellow of the Royal Society of Canada, 2000
• Honoree, Farha Foundation, 1999
• Prix Galien for pharmaceutical research (shared with scientists from BioChem Pharma, Inc.) for work leading to the discovery and development of lamivudine, 1996
  
  
  

Education

• McGill University, BSc (1966)
• Columbia University, PhD (1972)
• Hebrew University-Hadassah Medical School, Jerusalem, Israel, Postdoctoral Fellow (1972-1974)
• National Institutes of Health, visiting scientist (1980-1981)
  
  
  

Selected Publications

1. Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm³: a double-blind, randomized, controlled trial. The Canadian HIV Trials Network Protocol 002 Study Group. Ann Intern Med. 1995;123:561-571.
2. Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak M, Gu Z, Song Q, Manne J, Islam S, Castriota G, Prasad VR. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 1996;271:1282-1285.
3. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA. 1998;279:1977-1983.
4. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, Lamy PD, Margot NA, Anton KE, Cherrington JM. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999;4:87-94.
5. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Cote P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP, Newly Investigators of the Quebec Primary Infection Study. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS. 2000;14:F17-F23.
6. Gotte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol. 2000;74:3579-3585.
7. Kameoka M, Rong L, Gotte M, Liang C, Russell RS, Wainberg MA. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. J Virol. 2001;75:2675-2683.
8. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol. 2002;76:1753-1761.
9. Brenner B, Routy JP, Quan Y, Moisi D, Oliveira M, Turner D, Wainberg MA; Co-Investigators of the Quebec Primary Infection Study. Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS. 2004;18:1653-1660.
10. Quan Y, Brenner BG, Oliveira M, Wainberg MA. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother. 2003;47:747-754.